KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Assets Average (2018 - 2025)

Historic Assets Average for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $355.6 million.

  • Esperion Therapeutics' Assets Average rose 670.31% to $355.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.6 million, marking a year-over-year increase of 670.31%. This contributed to the annual value of $274.8 million for FY2024, which is 2113.17% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Assets Average is $355.6 million, which was up 670.31% from $335.6 million recorded in Q2 2025.
  • Esperion Therapeutics' Assets Average's 5-year high stood at $362.7 million during Q2 2024, with a 5-year trough of $213.6 million in Q4 2023.
  • Over the past 5 years, Esperion Therapeutics' median Assets Average value was $308.4 million (recorded in 2022), while the average stood at $300.0 million.
  • In the last 5 years, Esperion Therapeutics' Assets Average skyrocketed by 6033.54% in 2021 and then plummeted by 3101.49% in 2023.
  • Esperion Therapeutics' Assets Average (Quarter) stood at $303.4 million in 2021, then dropped by 7.59% to $280.4 million in 2022, then dropped by 23.84% to $213.6 million in 2023, then surged by 54.05% to $329.0 million in 2024, then rose by 8.08% to $355.6 million in 2025.
  • Its Assets Average was $355.6 million in Q3 2025, compared to $335.6 million in Q2 2025 and $333.9 million in Q1 2025.